NextCure(NXTC) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, NextCure, Inc. reported approximately $41.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2027[4] - NextCure's financial resources are currently unaudited and subject to adjustment, as the consolidated financial statements for the year ended December 31, 2025, have not yet been finalized[5] - The company has a history of significant losses and relies on obtaining additional financing to support its operations[11] Clinical Trials and Studies - The SIM0505 Phase 1 study results are anticipated to be presented in Q2 2026, focusing on patients with advanced solid tumors, particularly platinum-resistant ovarian cancer[9] - Dosing has commenced in higher dose cohorts for the LNCB74 Phase 1 study, with proof-of-concept data now expected in the second half of 2026 due to enrollment delays[9] - The company is adding clinical sites and increasing drug supply for the SIM0505 study in anticipation of initiating dose optimization in the first half of 2026[9] Corporate Strategy and Operations - The company is focused on the development of its two antibody drug conjugate (ADC) programs, which are critical to its future growth strategy[8] - The company updated its corporate presentation on January 23, 2026, which includes additional insights into its operations and future plans[6] Market and Risks - NextCure's common stock is listed on the Nasdaq Global Select Market, and the company must maintain this listing[11] - Forward-looking statements regarding the company's financial performance and clinical trials involve substantial risks and uncertainties[11]